Orthofix Medical Inc (NASDAQ:OFIX) has been assigned a consensus rating of “Hold” from the six research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $60.00.
Several analysts have recently commented on OFIX shares. ValuEngine downgraded shares of Zymeworks from a “buy” rating to a “hold” rating in a research report on Saturday, May 18th. TheStreet downgraded shares of Trade Desk from a “b-” rating to a “c-” rating in a research report on Thursday, May 9th. Zacks Investment Research downgraded shares of ExlService from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, BidaskClub downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday.
In related news, CEO Brad Mason sold 8,890 shares of the stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $51.11, for a total value of $454,367.90. Following the transaction, the chief executive officer now directly owns 159,053 shares in the company, valued at approximately $8,129,198.83. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last quarter, insiders sold 25,507 shares of company stock worth $1,338,776. 5.60% of the stock is owned by company insiders.
Shares of OFIX stock traded down $0.31 during trading hours on Friday, hitting $51.55. 52,560 shares of the company were exchanged, compared to its average volume of 122,960. The stock has a market capitalization of $988.76 million, a price-to-earnings ratio of 26.30, a P/E/G ratio of 2.92 and a beta of 0.44. Orthofix Medical has a fifty-two week low of $47.79 and a fifty-two week high of $74.44. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.28 and a current ratio of 3.52. The company’s 50 day simple moving average is $51.24.
Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings data on Monday, May 6th. The medical device company reported $0.27 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.13). The company had revenue of $109.10 million for the quarter, compared to analyst estimates of $110.59 million. Orthofix Medical had a return on equity of 10.45% and a net margin of 2.09%. The business’s quarterly revenue was up .4% compared to the same quarter last year. During the same period last year, the business earned $0.39 EPS. On average, analysts anticipate that Orthofix Medical will post 1.77 earnings per share for the current fiscal year.
About Orthofix Medical
Orthofix Medical Inc, a medical device company, provides musculoskeletal healing products and therapies worldwide. It operates through four segments: Bone Growth Therapies, Spinal Implants, Biologics, and Orthofix Extremities. The Bone Growth Therapies segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spinal appendicular fractures.
Recommended Story: Using the New Google Finance Tool
Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.